Croda and AAHI partner to drive innovation in vaccine development
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
A significant proportion of healthcare professionals still tend to favor branded drugs
Total value of the supplies of FC will be US$ 2.773 million
Subscribe To Our Newsletter & Stay Updated